Recent Blog Posts

View Post: Histone Deacetylase Inhibitors Induce a Very Broad, Pleiotropic ...
1 Jun 2009 by Hauswald, S., Duque-Afonso, J., Wagner,...  
Histone Deacetylase Inhibitors Induce a Very Broad, Pleiotropic Anticancer Drug Resistance Phenotype in Acute Myeloid Leukemia Cells by Modulation of Multiple ABC Transporter Genes. Stefanie Hauswald1,; Jesus Duque-Afonso2, ...
View Blog: Clinical Cancer Research recent issues - http://clincancerres.aacrjournals.org/

---

View Post: An Article on Cancer
Cancer
Health Press ...
View Blog: There has been an anticancer drug that kills cancer cells while leaving the good ones alive. This drug was introduced in the spring of 2001. The drug, Gleevec has proven to work very strongly against chronic myelogenous leukaemia,

---

View Post: Leukemia Chemotherapy - Benefits And Side Effects
13 Nov 2009 by Kathy  
Chemotherapy for treating leukemia varies greatly because leukemia is of several types. Generally, leukemia treatment combines chemotherapy with various anticancer drugs that destroy cancer cells by preventing them from growing and ...
View Blog: Women Health Info - http://womenwellnessinfo.blogspot.com/

---

View Post: Your Pharmacy in the neighbourhood
Leukemia commonly used ...
4 Oct 2009 ...
View Blog: http://1stpharmacy.cn/

---

View Post: Homeopathy Approch in Stomach Cancer and Its Managment
19 Nov 2009 by hair extensions professional  
Generally, anticancer drugs affect cells that divide rapidly. These include blood cells, which fight infection, help the blood to clot, or carry oxygen to all parts of the body. When blood cells are affected by anticancer drugs, ...
View Blog: Hair Extensions How To - http://hairextensionshowto.co.uk/

---

View Post: Orphan drug designation granted to voreloxin for acute myeloid ...
5 Nov 2009
Sunesis Pharmaceuticals was granted orphan drug designation by the FDA for its drug candidate, voreloxin for the treatment of acute myeloid leukemia (AML). ... Voreloxin is a first-in-class anticancer quinolone derivative, or AQD, a class of compounds that has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, G2 arrest and apoptosis. ...
View Blog: Latest articles from MPR - http://www.empr.com/

---

View Post: Synta Presents Preclinical Data on Next Generation Hsp90 Inhibitor ...
18 Nov 2009
Broad anti-cancer activity as a single agent and in combination - Strong potency against highly resistant cancers - Superior profile to first generation Hsp90. ... Examples of cancer-associated client proteins of Hsp90 include KIT in gastrointestinal stromal tumors, epidermal growth factor receptor (EGFR) in lung cancer, and BCR-ABL in chronic myelogenous leukemia. In preclinical studies, inhibiting Hsp90 causes the degradation of these proteins and cancer cell death. ...
View Blog: Drugs.com - Clinical Trials - http://www.drugs.com/clinical_trials.html

---

View Post: Leukemia Clinical Trial: Tetradecanoylphorbol Acetate ...
5 Nov 2009
Tetradecanoylphorbol Acetate, Dexamethasone, and Choline Magnesium Trisalicylate in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia. RATIONALE: Drugs used in chemotherapy, such as tetradecanoylphorbol acetate, dexamethasone, ... More than 30 days since prior and no other concurrent investigational drugs; No concurrent herbal remedies; No other concurrent chemotherapy, immunotherapy, anticancer hormonal therapy, radiotherapy, or surgery for cancer ...
View Blog: Clinical Trials Updates During the Last 7 Days - http://clinicaltrialsfeeds.org/clinical-trials/r...

---

View Post: Homeopathy Approch in Stomach Cancer and Its Managment
14 Nov 2009 by admin  
Chemotherapy —the side effects of chemotherapy depends mainly on the drugs and doses the patient receives. Generally, anticancer drugs affect cells that divide rapidly. These include blood cells, which fight infection, help the blood to ...
View Blog: Medical Health Center - http://www.themedicalcenters.com/

---

View Post: How Cells Tolerate DNA Damage – MDC Researchers Identify Start ...
23 Nov 2009 by admin  
Monitoring and Adherence in CMLImatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. Monitoring and Adherence in CMLImatinib, or Gleevec, ...
View Blog: Genetherapy - http://www.genetherapy.me/

---